Jefferies analyst Biren Amin said feedback he's received from management at The Medicines Co. suggests that talks about the company's strategic process began in January and that there are "several interested parties" involved. Management added that they will stay open to discussions until "significant" patient enrollment has occurred in their Phase 3 trail, Amin added. The analyst, who thinks a 13-15 month timeframe is a reasonable one to expect for the process to come to a conclusion, keeps a Buy rating and $62 price target on Medicines Co. shares.